Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of $4.4 billion as of September 30, 2025, supporting cash runway into profitability
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- ROIV Upcoming Earnings Report: What to Expect?
- Vor Bio appoints Sokolove as Chief Medical Officer
- Roivant Sciences price target raised to $25 from $16 at Citi
- Roivant Sciences files automatic mixed securities shelf
- Hold Rating for Roivant Sciences Amid Promising Developments and Competitive Challenges